Treats symptomatic benign prostatic hyperplasia (BPH). ANDA 207769, held by Zydus Pharms. Dutasteride; Tamsulosin Hydrochloride.
As of Nov 16, 2026, ANDA 207769 (Dutasteride And Tamsulosin Hydrochloride), held by Zydus Pharms, was first approved by FDA on May 24, 2018, with 1 approved supplement and 0 published complete response letters.
Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5 alpha-reductase inhibitor, and tamsulosin, an alpha adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer. 1.1 Benign Prostatic Hyperplasia (BPH) Treatment Dutasteride and tamsulosin hydrochloride capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 24, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dutasteride And Tamsulosin Hydrochloride0.5MG;0.4MG · capsule;oral | Dutasteride; Tamsulosin Hydrochloride | Rx |
| Mar 1, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 24, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters